Singulex enables critical research about disease and therapeutic intervention by providing cutting edge immunodiagnostic products and personalized services.
Singulex, Inc. has pioneered single-molecule counting technology that can quantitatively measure single molecules such as proteins and metabolites directly in complex biological samples without abundant protein stripping techniques. We provide instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy.
In addition, we focus on advancing industry-leading sample analysis and custom assay development services. Our team of scientists are experts in the field of immunoassay development and our manufacturing department ensures that products are produced with the highest standards.
Leveraging upon the Singulex technology, our CVMedHome Offering empowers physicians and patients to better manage heart health with a unique cardiovascular wellness management program. The CVMedHome offering includes enhanced cardiovascular profiling services featuring ultrasensitive Sgx HD™ immunoassays, a personalized wellness program, and online interactive management tools.
No reviews to display
The Erenna Immunoassay System , powered by Singulex's patented single-molecule detection technology, accelerates biomedical and translational resear...
More about the High-Definition Erenna® Immunoassay System
New Data from TIMI Study Group to Be Presented at American College of Cardiology Scientific Session Show Prognostic Value of High-Precision Cardiac Troponin Monitoring
17 Apr 2013
01 Nov 2012
17 May 2012
Highly Sensitive Cardiac Troponin-I Assay Could Identify Future Risk for Dying from Cardiovascular Disease
17 May 2012
01 Mar 2012
05 Nov 2012
09 Oct 2012
Elevations of Intracellular Kinases AKT1, GSK3β, JNK2 and ERK2 in Primary Breast Cancer Tissue Quantified with a Novel Multi-panel of Single Molecule ImmunoassaysSingulex
03 Apr 2012
Elevations of Cardiac Troponin‐I Quantified with the Erenna® cTnI Immunoassay are an Early Indicator of Heart Muscle Injury in Studies of CardiotoxicitySingulex
30 Mar 2012
Advanced Single Molecule Detection: Accelerating Biomarker Development Utilizing Cytokines Through Ultrasensitive ImmunoassaysSingulex
16 Mar 2012